Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical raw material as well as preparation and application thereof

A technology for pharmaceutical preparations and raw materials, applied in the field of medicine, can solve problems such as research on the composition of raw materials of Buxycin D without cyclovir

Active Publication Date: 2013-06-26
西藏易明西雅医药科技股份有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The document "Study on the Mechanism of Hepatotoxicity of Cycloviral Boxuxin D" discloses the raw material of Cycloviral Boxuxin D (cycloviral Boxuxin D is an active ingredient of traditional Chinese medicine, which is obtained by extraction and purification methods; according to the prior art methods, it is impossible to obtain absolute 100% substance, which must contain certain impurity components) has certain liver toxicity after oral administration, but there is no in-depth research on the raw material composition of Cyclovirubuxin D in this document

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical raw material as well as preparation and application thereof
  • Medical raw material as well as preparation and application thereof
  • Medical raw material as well as preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0129] A pharmaceutical raw material, wherein the weight content of cyclovirbuxine D is 95.7%, the weight content of cycloevergreen boxine C is 3.9%, and the remaining impurities are 0.4%.

[0130] The above raw materials are prepared into aqueous injections, transfusions, powder injections, tablets, capsules and the like.

[0131] Wherein the aqueous injection is composed of: 1 g of Cycloviral Buxusin D raw material, 1000 ml of water for injection, an appropriate amount of tris-hydrochloric acid buffer solution (adjusting the pH value to 5.0); or 1 g of Cycloviral Buxusin D raw material, 1000 ml of water for injection, Appropriate amount of citric acid (adjust pH=5.0).

[0132]The composition of the powder injection: 1 g of cyclovir buxus D raw material, 1000 ml of water for injection, 50 g of mannitol, an appropriate amount of tris-hydrochloric acid buffer solution (adjust the pH value to 5.0); or 1 g of cyclovir buxuxin D raw material, manna Alcohol 50g, water for injectio...

Embodiment 2

[0134] A pharmaceutical raw material, wherein the weight content of cyclovirbuxine D is 99.1%, the weight content of cycloevergreen boxine C is 0.7%, and the remaining impurities are 0.2%.

[0135] The above raw materials are prepared into aqueous injections, transfusions, powder injections, tablets, capsules and the like.

[0136] Wherein the water injection is composed of: 2 g of cyclovir buxicine D raw material, 2000 ml of water for injection, an appropriate amount of tris-hydrochloric acid buffer solution (adjusting the pH value to 5.5); or 2 g of cyclovir buxicine D raw material, 2000 ml of water for injection, An appropriate amount of citric acid (adjust pH=5.5).

[0137] The composition of the powder injection: 2 g of cyclovir buxus D raw material, 2000 ml of water for injection, 50 g of mannitol, an appropriate amount of tris-hydrochloric acid buffer solution (adjust the pH value to 5.5); or 2 g of cyclovir buxuxin D raw material, manna Alcohol 50g, water for injectio...

Embodiment 3

[0139] A pharmaceutical raw material, wherein the weight content of cyclovirbuxine D is 99.3%, the weight content of cycloevergreen boxine C is 0.5%, and the remaining impurities are 0.2%.

[0140] The above raw materials are prepared into aqueous injections, transfusions, powder injections, tablets, capsules and the like.

[0141] Wherein the water injection is composed of: 2 g of cyclovir buxicine D raw material, 2000 ml of water for injection, an appropriate amount of tris-hydrochloric acid buffer solution (adjusting the pH value to 5.5); or 2 g of cyclovir buxicine D raw material, 2000 ml of water for injection, An appropriate amount of citric acid (adjust pH=5.5).

[0142] The composition of the powder injection: 2 g of cyclovir buxus D raw material, 2000 ml of water for injection, 50 g of mannitol, an appropriate amount of tris-hydrochloric acid buffer solution (adjust the pH value to 5.5); or 2 g of cyclovir buxuxin D raw material, manna Alcohol 50g, water for injectio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of traditional Chinese medicines and discloses a medical raw material as well as a preparation and an application thereof. The medical raw material comprises cyclovirobuxine D and cyclovirobuxine C. Through researches, people find that the content of cyclovirobuxine C in the raw material of cyclovirobuxine D is within a certain range, so that the hepatotoxicity of the raw material is remarkably reduced; and proved by pharmacodynamic tests, the raw material of cyclovirobuxine D disclosed by the invention has a favorable effect for treating angina, coronary disease and arrhythmia.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a drug raw material of cyclovirbuxine D and its preparation and application. Background technique [0002] Huangyangning preparation is a preparation prepared from the Buxus family plant-Buxus microphylla as the raw material. It is the first new drug for the treatment of cardiovascular and cerebrovascular diseases in my country. Among them, Huangyangning tablet has been included in the 2000, 2005, and 2010 editions of the Chinese Pharmacopoeia. The above-mentioned medicines belong to traditional Chinese medicine. Traditional Chinese medicine plays an important role in the treatment of diseases in clinical application. However, traditional Chinese medicine is mostly used as compound medicinal materials or compound extracts. The composition is complex, and unknown non-quantitative components occupy a considerable proportion. There are too many, the curative substances ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07J53/00A61K31/57A61P9/10A61P9/06
Inventor 曹捷高帆周战尚磊
Owner 西藏易明西雅医药科技股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com